NDA 022181/S-024
NDA 205065/S-008

SUPPLEMENT APPROVAL

BioMarin Pharmaceutical Inc.
Attention: Christine-Marie Feron, PharmD, MPH
Senior Director, Regulatory Affairs Global Labeling
105 Digital Drive
Novato, CA 94949

Dear Dr. Feron:

Please refer to your supplemental new drug applications (sNDAs) dated and received March 8, 2024 (NDA 022181/S-024) and August 2, 2024 (NDA 205065/S-008), and your amendments to NDA 022181/S-024, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kuvan (sapropterin dihydrochloride) tablets and Kuvan (sapropterin dihydrochloride) powder for oral solution, respectively.

These Prior Approval sNDAs provide for updates to the Kuvan Prescribing Information with data from the PKU Maternal Phenylketonuria Observational Program (PKU MOMS) registry and the Kuvan Adult Maternal Paediatric European Registry (KAMPER), along with other updates.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your applications, you are exempt from this requirement.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of these supplements for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDAs that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplements pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Diego Diaz, Regulatory Project Manager, via email at Diego.Diaz@fda.hhs.gov or at (301) 796-7182.

Sincerely,

{See appended electronic signature page}

Yuliya Yasinskaya, M.D.
Deputy Director
Division of Rare Diseases and Medical Genetics (DRDMG)
Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM)
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert (Previously Approved on March 16, 2020)
  - Instructions for Use (Previously Approved on March 16, 2020)

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

YULIYA I YASINSKAYA
09/05/2024 09:04:27 AM